This web site uses cookies. Do you accept the use of external cookies? Yes No Know more x
Survey about achondroplasia
We have designed a questionnaire with the purpose to better know the population connected to achondroplasia.
The questionnaire is optional and anonymous. The data obtained will be used for statistical purposes and to better understand the natural history of achondroplasia. Please consider answering.
If you would like to take the survey later, you can click on the link at the top "Register at BA"
Go to the survey Not now No, thanks

Industry

Ascendis Pharma


Ascendis Pharma is developing TransCon CNP, which had positive results in pre-clinical studies. The company aims to release new data on a phase I clinical trial in the fourth quarter of 2018.

Visit their website.

BioClin Therapeutics, Inc


Pipeline


BioclinTherapeutics pipeline
Adapted from: BioClin Therapeutics (08/2017)

Visit their website. 

BioMarin


Pipeline


Biomarin Pipeline v2
Adapted from: BioMarin (08/2017)

Visit their website.

Ribomic


Pipeline


Ribomic Pipeline




Adapted from: Ribomic (09/2017)

Visit their website.

Therachon


Therachon is developing TA-46, which has already acquired Orphan Drug status and is heading towards phase II clinical trial, which is planned for the beginning of 2019. The company has also announced that they are developing another drug for achondroplasia called TA-100.


Pipeline

TA 46 pipelineTA 100 pipeline
Visit their website.

To view this site you need Internet Explorer 8 (or a higher version)
or another internet browser.

Thank You.